内幕Jessica Sachs在12月26日出售了320万加元的Cogent生物科学股份,将其股份减少了38%。 Insider Jessica Sachs sold $3.2M in Cogent Biosciences stock on Dec. 26, reducing her stake by 38%.

2025年12月26日, Cogent Biosciences Interrior Jessica Sachs出售82,642股,每股38.70美元,净值约320万美元,将股份减少38.16%。 On December 26, 2025, Cogent Biosciences insider Jessica Sachs sold 82,642 shares at $38.70 each, netting about $3.2 million and reducing her stake by 38.16%. 该公司开发针对肿瘤微环境的小型分子疗法,报告第三季度损失了每股0.50美元,略高于估计的0.54美元。 The company, developing small-molecule therapies targeting the tumor microenvironment, reported a third-quarter loss of $0.50 per share, slightly better than the estimated $0.54. 它的主要药物候选者 正在早期试验固态肿瘤 Its lead drug candidate is in early-stage trials for solid tumors. 股票在12月23日以37.12美元关闭, 市场上限为52.9亿美元, The stock closed at $37.12 on December 23, with a market cap of $5.29 billion and a consensus "Moderate Buy" rating.